Biogen Inc. has announced its financial results for the third quarter of 2026, showcasing a strong performance that underscores the company's recovery and growth trajectory. The report, filed on October 28, 2026, highlights total revenue of $2.8 billion, marking an 11% increase compared to the same period last year. This growth is largely attributed to the success of Biogen's Growth Portfolio, which includes contributions from newly acquired products from Apellis.

Christopher A. Viehbacher, President and Chief Executive Officer of Biogen, expressed optimism regarding the company's performance, stating, “Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”

Background

Biogen Inc. operates in the biological products sector, specifically focusing on biological products (no diagnostic substances), as classified under SIC code 2836. The company trades under the ticker symbol BIIB on the Nasdaq exchange. As a large accelerated filer, Biogen is subject to rigorous reporting requirements and has a history of significant filings, including recent reports on October 5 and July 29, 2026.

What the Filing Says

The filing details the results of operations and financial condition for the third quarter ended September 30, 2026. It states, “On October 28, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter.” The press release is incorporated as Exhibit 99.1 in the filing.

Impact

These results are significant not only for Biogen but also for the broader biological products industry. The reported revenue growth may affect competitors and market dynamics, particularly those also involved in the development and marketing of similar biological products. The performance of Biogen's Growth Portfolio, particularly with the integration of Apellis products, may set a benchmark for other companies in the sector.

What's Next

The filing does not specify what happens next. However, with multiple Phase 3 readouts expected over the next 12 months, Biogen is positioned to further strengthen its growth profile and enhance shareholder value.